TherapeuticsMD (NASDAQ:TXMD) Upgraded to “Sell” by BidaskClub

BidaskClub upgraded shares of TherapeuticsMD (NASDAQ:TXMD) from a strong sell rating to a sell rating in a research note issued to investors on Saturday, BidAskClub reports.

Several other equities analysts have also commented on the stock. Oppenheimer reduced their target price on shares of TherapeuticsMD from $13.00 to $10.00 and set an outperform rating on the stock in a report on Tuesday, June 11th. Jefferies Financial Group dropped their price target on shares of TherapeuticsMD from $4.00 to $3.00 and set a hold rating for the company in a research report on Monday, July 15th. Noble Financial reissued an outperform rating and set a $13.00 price target on shares of TherapeuticsMD in a research report on Tuesday, April 30th. ValuEngine raised shares of TherapeuticsMD from a sell rating to a hold rating in a research report on Thursday, August 1st. Finally, JPMorgan Chase & Co. dropped their price target on shares of TherapeuticsMD from $8.00 to $6.00 and set a buy rating for the company in a research report on Tuesday, June 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $9.28.

Shares of TXMD stock traded up $0.46 on Friday, hitting $3.10. 9,594,457 shares of the company’s stock traded hands, compared to its average volume of 3,124,285. The company has a quick ratio of 3.28, a current ratio of 3.39 and a debt-to-equity ratio of 1.26. TherapeuticsMD has a one year low of $1.82 and a one year high of $6.94. The firm’s fifty day moving average is $2.42. The stock has a market cap of $636.83 million, a PE ratio of -5.25 and a beta of 1.90.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Tuesday, August 6th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.01). TherapeuticsMD had a negative net margin of 913.07% and a negative return on equity of 163.84%. The business had revenue of $6.08 million for the quarter, compared to the consensus estimate of $5.12 million. During the same period in the prior year, the business posted ($0.15) EPS. TherapeuticsMD’s revenue for the quarter was up 60.0% on a year-over-year basis. As a group, equities research analysts anticipate that TherapeuticsMD will post -0.71 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in TXMD. Moors & Cabot Inc. purchased a new stake in shares of TherapeuticsMD in the 2nd quarter worth about $25,000. Moloney Securities Asset Management LLC purchased a new stake in shares of TherapeuticsMD in the 2nd quarter worth about $27,000. H D Vest Advisory Services purchased a new stake in shares of TherapeuticsMD in the 2nd quarter worth about $34,000. Advisor Group Inc. lifted its position in shares of TherapeuticsMD by 73.2% in the 2nd quarter. Advisor Group Inc. now owns 13,960 shares of the company’s stock worth $36,000 after purchasing an additional 5,900 shares during the period. Finally, Private Ocean LLC purchased a new stake in shares of TherapeuticsMD in the 1st quarter worth about $37,000. 79.86% of the stock is owned by institutional investors and hedge funds.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Featured Article: Municipal Bonds

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.